Assessment of everolimus in addition to calcineurin inhibitors reduction in maintenance renal transplant recipients (ASCERTAIN)

Registry ID
EUCTR2004-002267-24
Source registry
EUCTR
Status
Completed
Phase
PHASE3
Sponsor
Novartis Pharma Services AG
Start date
2005-07-29
Completion date
2009-08-18
Last update
2026-08-16

Conditions

Summary

The primary objective is to investigate whether initiation of everolimus together with reduction or discontinuation of CNI in maintenance renal transplant patients with renal impairment will improve renal function. This will be assessed by comparing renal function evaluated by measured glomerular filtration rate among 3 groups of patients at month 24.

Locations

View on source registry